CClinicalTrials.gg
Status unknownNCT02858141Updated Aug 8, 2016

Onco-geriatric Database of Patients With Pancreatic Cancer

An observational study in Pancreatic Neoplasms, sponsored by Institut Paoli-Calmettes. Status unknown at 2 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2016-08-08.

Sponsored by Institut Paoli-Calmettes · Observational

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
70 Years and older
Sex
All
01

Study summary

This data base has been set in order to gather oncogeriatric information from elderly patients with pancreatic cancer who underwent an oncogeriatric evaluation.

ONCOGEPAN database gathers data from deux institutions (Institut Paoli-Calmettes and Assistance Publique des Hôpitaux de Marseille) involved in Marseille SIRIC (Integrated Cancer Research Site).

02

Conditions studied

  • Pancreatic Neoplasms

Keywords

  • oncogeriatric evaluation
  • pancreatic cancer
  • Database
03

In context

Pancreatic Neoplasms

3,235 studies on the registry are indexed under Pancreatic Neoplasms; 898 are open to participants now.

This study's planned enrollment of 300 is above the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Institut Paoli-Calmettes is the lead sponsor of 168 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Elderly patients with pancreatic cancer who underwent an oncogeriatric evaluation

Inclusion criteria

  • Age>70 years
  • Oncogeriatric evaluation done

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • OtherData collection
06

What researchers measure

Primary outcomes

  1. Collection of oncogeriatric data for future research studies

    Time frame: 5 years

07

Study locations

2 of 2 sites recruiting
  • Institut Paoli Calmettes
    Marseille, Bouches du Rhône 13009, France
    Recruiting
  • Assistance Publique des Hôpitaux de Marseille
    Marseille, Bouches du Rhône 13385, France
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02858141
Lead sponsor
Institut Paoli-Calmettes
Responsible party
Sponsor
First posted
Aug 8, 2016
Start date
May 2015
Primary completion
May 2020 (estimated)
Last update
Aug 8, 2016

Study contacts

Dominique Genre, MD
Contact
drci.up@ipc.unicancer.fr
0033491223778
Lilian Laborde
Contact
labordel@ipc.unicancer.fr
0033491223778
Elodie Crétel
principal investigator · Assistance Publique des Hôpitaux de Marseille
Frédérique Rousseau
principal investigator · Institut Paoli-Calmettes

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion